Study S000917

SURE SWITZERLAND: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03631186
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 215
Start: 2018-09-12
Primary completion: 2019-12-18
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1207-6039

Registered primary outcomes

Change in Glycated Haemoglobin A1c (HbA1c) [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]
Change in HbA1c [Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008328	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. Yale JF, BMJ open diabetes research & care	2022	Nonrandomized study	PMID 35383100 DOI	cites ClinicalTrials.gov:NCT03631186; registry reference DERIVED:35383100
R0023109	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. Rudofsky G, Diabetes research and clinical practice	2021	Nonrandomized study	PMID 34217773 DOI	cites ClinicalTrials.gov:NCT03631186; registry reference RESULT:34217773